drugset / Trial / NCT00974896
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo cohorts are enrolling. All other combo cohorts are closed to enrollment.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-09
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganitumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Ganitumab | Monoclonal antibody | 12 mg/kg | Intravenous |